Deca N 200mg/ml 10x1ml Ampullen by Raw Pharma

Usage

1. Confirm your weekly cutting dose (150–250 mg) and calculate the corresponding volume from the 200 mg/ml concentration before drawing. A 200 mg dose = 1.0 ml; a 150 mg dose = 0.75 ml.
2. Break the ampoule using the snap-off point after warming briefly in your hands to reduce oil viscosity — do not use heat sources. Draw the full calculated volume with an 18–21 G drawing needle.
3. Switch to a 23–25 G injection needle appropriate for intramuscular administration. Preferred sites during a cutting phase are the glute or vastus lateralis — rotate sites weekly to avoid localised tissue irritation.
4. Apply standard aseptic technique: clean the injection site with an alcohol swab, aspirate briefly, then inject slowly over 10–15 seconds to minimise discomfort from the oil depot.
5. Discard the opened ampoule and used needle immediately after a single injection event — the single-dose format means no partial volumes should be stored or reused.
6. Log each injection date, volume, and site. During a cutting cycle this record also helps you time cessation correctly — stopping Deca N 3 weeks before your planned PCT start requires knowing your exact injection timeline.

Warnings

Frequently asked questions

Can Nandrolone Decanoate be used effectively during a cutting phase rather than just for bulking?

Yes — Nandrolone Decanoate is genuinely effective in a cutting phase, primarily as an anti-catabolic agent rather than a mass-builder. By maintaining positive nitrogen balance in skeletal muscle during caloric restriction, it limits the lean-tissue losses that aggressive dieting typically causes. At 150–250 mg per week, the compound delivers this protective effect with minimal fluid retention due to its low aromatisation rate.

What weekly dose of Nandrolone Decanoate is appropriate for a cutting cycle compared to an off-season bulk?

Cutting-phase doses are substantially lower than off-season loading doses. Most structured cutting protocols position Nandrolone Decanoate at 150–250 mg per week — enough to sustain anti-catabolic androgen receptor activity in myocytes without promoting the excess water retention or appetite stimulation associated with higher supraphysiological doses used during mass phases.

Which compounds pair well with Nandrolone Decanoate in a cutting stack?

The most logical cutting partners are a low-to-moderate dose testosterone base — essential to maintain androgenic tone that nandrolone alone does not fully sustain — alongside a dry oral compound such as Anavar (Oxandrolone) to enhance muscle hardness without significant aromatisation. Non-aromatising injectables like Primobolan are also commonly combined with Nandrolone Decanoate during definition phases.

Why does the single-dose ampoule format of Raw Pharma Deca N matter for a cutting cycle specifically?

Cutting cycles typically run 10–16 weeks with frequent, precisely measured injections. Single-dose ampoules ensure each draw comes from a sterile, unopened container, eliminating the contamination risk that accumulates when a multi-dose vial is punctured repeatedly over weeks. This is particularly relevant during cuts when immune resilience may be reduced by caloric restriction.

How should Raw Pharma Deca N 10x1ml ampoules be stored to maintain potency across a multi-week cutting cycle?

Store ampoules at 15–25 °C, away from direct light and moisture, in their original packaging until use. Do not refrigerate oil-based injectables, as cold temperatures can cause the oil carrier to thicken and increase injection resistance. Each ampoule is single-use — open immediately before injection and discard the entire contents; no portion should be retained after breaking the ampoule seal. (2) angle_used

Manufacturer

Raw Pharma operates under a GMP-certified quality framework applied uniformly across its injectable product range, including Deca N. The company's certification scope covers sterile fill-and-finish operations for oil-based parenteral products: each production run is subject to HPLC potency analysis confirming the 200 mg/ml active-ingredient specification within accepted pharmacopoeial tolerances, followed by LAL endotoxin testing against parenteral-grade safety thresholds before any batch is released. Raw Pharma's quality documentation system assigns a Certificate of Analysis to each batch at the point of production — not retrospectively — ensuring traceability is embedded in the manufacturing sequence rather than appended as an afterthought. The single-dose ampoule chosen for Deca N reflects a container-selection decision aligned with GMP sterility principles: Type I borosilicate glass ampoules sealed without preservative require no antimicrobial adjuvant, meaning the formulation itself remains a clean two-component system of active pharmaceutical ingredient and pharmaceutical-grade oil carrier.